Drug Trial Radar · NCT06328725
Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy
Last checked: Nov 20, 2026Latest source record: Mar 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
88
Planned (sponsor's estimate)
Start
Mar 2024
Primary completion
Nov 2025
Study completion Nov 2025
Sponsor
- Lead sponsor
- ENCellIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Duchenne Muscular Dystrophy
Conditions
- Duchenne Muscular Dystrophy
Interventions
EN001Drug
Phase 1 * Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals. * Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals. Phase 2 * Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals. * Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- <Phase 1> Adverse drug reactions related to dose limiting toxicity (DLT)Time frame: Up to 14 weeks
- <Phase 1> Adverse drug reactions related to discontinuation of clinical trial drug administrationTime frame: Up to 14 weeks
- <Phase 2> Change in time to stand test (TTSTAND)Time frame: At 48 weeks compared to baseline (Visit 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.